

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/031366 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2022/074394

(22) International Filing Date:
01 September 2022 (01.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/240,134 02 September 2021 (02.09.2021) US

(71) Applicant: **DEUTSCHES KREBS-
FORSCHUNGSZENTRUM STIFTUNG DES ÖF-
FENTLICHEN RECHTS** [DE/DE]; Im Neuenheimer
Feld 280, 69120 Heidelberg (DE).

(72) Inventors: **TRAUTWEIN, Mark**; Narzissenweg 4, 42489
Wülfrath (DE). **WILLUDA, Jörg**; Staerkstr. 47a, 16548
Glienicke/Nordbahn (DE). **DÖCKE, Wolf-Dietrich**; Pal-
isadenstrasse 37d, 10243 Berlin (DE). **BUCHMANN, Pas-
cale**; Pastorskamp 31, 51381 Leverkusen (DE). **CAR-
RETERO, Rafael**; Mühlingstraße 6, 69121 Heidelberg
(DE). **ELLINGER, Philipp**; Blaupfeilweg 29, 42697
Solingen (DE). **OFFRINGA, Rienk**; Deutsches Krebs-
forschungszentrum, Innovations-Management, T010, Im
Neuenheimer Feld 280, 69120 Heidelberg (DE). **NOGAI,
Franz Hendrik**; Melchtalstrasse 15, 4102 Binningen (CH).
PAZ, Pedro; 133 Rocky Pointe Ct, Hercules, California
94547 (US).

(74) Agent: **ALTMANN STÖSSEL DICK PATENTAN-
WÄLTE PARTG MBB**; Theodor-Heuss-Anlage 2, 68165
Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: ANTI-CECAM6 ANTIBODIES WITH REDUCED SIDE-EFFECTS

(57) Abstract: The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.



WO 2023/031366 A1